Alleviation effects of dexmedetomidine on myocardial ischemia/reperfusion injury through fatty acid metabolism pathway via Elovl6
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112588 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Haozheng Yuan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xi Wu Road, Xi'an, Shaanxi 710004, China. Hauptthemen laut MEDLINE: Dexmedetomidine, Myocardial Reperfusion Injury, Fatty Acid Elongases, Myocytes, Cardiac. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Dexmedetomidine (Dex) is widely used in the sedation in intensive care units and as an anesthetic adjunct. Considering the anti-inflammatory and antioxidant properties of Dex, we applied in vivo rat model as well as in vitro cardiomyocyte models (embryonic rat cardiomyocytes H9c2 cells and neonatal rat cardiomyocytes, NRCMs) to evaluate the effects of Dex against myocardial ischemia reperfusion (I/R) injury. Transcriptomic sequencing for gene expression in heart tissues from control rats and Dex-treated rats identified that genes related to fatty acid metabolism were significantly regulated by Dex. Among these genes, the elongation of long-chain fatty acids (ELOVL) family member 6 (Elovl6) was most increased upon Dex-treatment. By comparing the effects of Dex on both wild type and Elovl6-knockdown H9c2 cells and NRCMs under oxygen-glucose deprivation/reoxygenation (OGD/R) challenge, we found that Elovl6 knockdown attenuated the protection efficiency of Dex, which was supported by the cytotoxicity endpoints (cell viability and lactate dehydrogenase release) and apoptosis as well as key gene expressions. These results indicate that Dex exhibited the protective function against myocardial I/R injury via fatty acid metabolism pathways and Elovl6 plays a key role in the process, which was further confirmed using palmitate exposure in both cells, as well as in an in vivo rat model. Overall, this study systematically evaluates the protective effects of Dex on the myocardial I/R injury and provides better understanding on the fatty acid metabolism underlying the beneficial effects of Dex.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xi Wu Road, Xi'an, Shaanxi 710004, China.
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xi Wu Road, Xi'an, Shaanxi 710004, China.
- Department of Cardiovascular Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xi Wu Road, Xi'an, Shaanxi 710004, China. Electronic address: yanzi015@mail.xjtu.edu.cn.
Zitieren
APA
Yuan, H., Guo, J., Wang, C., & Zhang, C. (2024). Alleviation effects of dexmedetomidine on myocardial ischemia/reperfusion injury through fatty acid metabolism pathway via Elovl6. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112588
Vancouver
Yuan H, Guo J, Wang C, Zhang C. Alleviation effects of dexmedetomidine on myocardial ischemia/reperfusion injury through fatty acid metabolism pathway via Elovl6. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112588
BibTeX
@article{Yuan2024,
author = {Yuan, Haozheng and Guo, Jingying and Wang, Congxia and Zhang, Chunyan},
title = {Alleviation effects of dexmedetomidine on myocardial ischemia/reperfusion injury through fatty acid metabolism pathway via Elovl6},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112588}
}
EUVIMED